Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP ...

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and …

DelveInsight's EGFR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
MSN on MSN

BeOne highlights phase 3 BRUKINSA data in older CLL patients and advances leadership position in BTK inhibitors (ONC)

New data presented at EHA 2026 showed durable long-term outcomes for BRUKINSA in patients aged 80 and older, while additional ...

DelveInsight Business Research, LLP: EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next ...

The outlook for the EGFR inhibitor market continues to be highly promising, supported by the increasing adoption of precision medicine in oncology and the broader use of targeted therapies across ...